NCT00251394 - Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

July 31, 2009

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

Rituxan

Given intravenously once weekly for four weeks.

DRUG

1018 ISS

Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston